antisense oligonucleotides
lung cancer therapy
control of lung cancer cell proliferation
ERC-funded MASCP project
mouse models of lung adenocarcinoma
preclinical models of lung adenocarcinoma
single gene
ERC PoC program
ERC PoC proposal
result of detailed mechanistic analyses of alternative splicing regulation
major mechanism of gene regulation
molecular mechanisms of gene regulation
successful valorisation
Valorisation of splice
patient-derived tumours
therapeutic value
mice
derived xenografts
cell growth
variety of patient
added value
therapeutic potential
tumour growth
novel class of reagents
assets
lack of efficient therapies
intellectual property protection
recruitment of venture capital
poor prognosis
funding
applications
context
fundamental knowledge
different messenger RNAs
proteins
market
gap
work
key roles
main experimental goal
previous optimization of dose
delivery route
available support
healthcare innovation funds
requests
high incidence
various stakeholders
neurodegenerative disease
plethora of pathologies
spin-off company
combination
society
treatments
chemotherapy
antagonistic functions
goals
Alterations